Masimo announced that the new generation SedLine brain function monitoring system was approved by the US Food and Drug Administration (FDA). In the future, it will help doctors monitor the brain status of patients undergoing anesthesia through bilateral collection and simultaneous processing of four EEG signals, and strengthen the signal processing engine function, which will help doctors understand the brain situation comprehensively.
The new generation SedLine provides an enhanced patient status index (PSi), which will also display more complete multiple brainwave analysis (DSA), showing the activity of both sides of the brain. If combined with RD SedLine EEG sensor, it can be used in combination with O3 local blood oxygen saturation meter and networking platform to have a deeper understanding of the patient’s brain.
Masimo new generation brain function monitoring system approved by FDA
Masimo is a global leader in non-invasive monitoring technology, trying to improve patient conditions at a lower cost. Joe Kiani, founder and CEO of Masimo, said that he expected the new generation SedLine to play an important role as another Masimo product, the SET blood oxygen detector.
SedLine equipment has been listed in the United States for more than 10 years, and was acquired by Masimo in 2010. Masimo first worked with Massachusetts General Hospital (MGH) to develop multiple brain wave analysis. In 2016, it reached technical cooperation with Philips, combining with Philips IntelliVue display, to highlight the brain response of patients after anesthesia.
0523-86890775
805 Health Avenue, Medical High-Tech Industry Development Zone Taizhou
bangtingyl@163.com
